Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Vonoprazan 20 mg, Esomeprazole.
- Who it may be relevant to
- Registry conditions: Erosive Esophagitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Indonesia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison of the Effectiveness of Vonoprazan and Esomeprazole in Improving Initial Symptoms in Patients with Erosive Esophagitis: a Double-Blind Randomized Trial
Overview
The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities. The main questions it aims to answer are: How does the effectiveness of Vonoprazan compare with Esomeprazole in improving early symptoms of erosive esophagitis patients in the Indonesian population? Researchers will compare drug vonoprazan to a esomeprazole with a look-alike packaging to see their effect to reduce early symptoms of erosive esophagitis. Participants will: * Take drug vonoprazan 20mg or esomeprazole 40mg one time every day for 2 weeks * Visit the clinic once every weeks for followup (Gastro Esophageal Reflux Disease-Quetionnaire measurement) * Keep a diary of their adverse effect occurence and every variable data based on Gastro Esophageal Reflux Disease-Questionnaire.
Detailed description
Based on the calculation using the formula for comparing two population proportions, the minimum estimated sample size is 97 samples for each group. Considering a potential 10% drop-out rate, the estimated sample size increases to 108 samples per group. Therefore, the total minimum sample required for this study is 216 samples for both groups.
All the patients will screened using the Gastro Esophageal Reflux Disease-Quetionnaire (6 questions, 4 answer options, covering the last 7 days) and collected through RedCap. After that all eligible patients will undergo endoscopic examination that performed by gastroenterology specialists or trained internists.
Included patients who consume any Proton Pump Inhibiotr or Potassium-competitive acid blockers within 2 weeks prior to this study will undergo wash-out period for 2 weeks. Patients are monitored weekly during the wash-out period. Medication reminders are sent via instant messaging at least twice per week. Adverse Event will be monitored by research assistants in coordination with the patient's primary physician.
All the data will analyzed blindly with Chi-square or Fisher's exact test for categorical data and logistic regression for confounding factors. At the end of the study, the pharmacy team will reveal the group allocation.
Interventions
- Drug Vonoprazan 20 mg
Vonoprazan PO, 20mg, once a day, 14 days. - Drug Esomeprazole
Esomeprazole PO, 40mg, once a day, 14 days
Primary outcome measures
- Number of Participants with Symptoms Resolution of Erosive Esophagitis [Time frame: 14 days (two weeks)]
Secondary outcome measures (1)
- Number of Participants with Adverse Event [Time frame: 14 days (two weeks)]
Eligibility criteria
Inclusion criteria
- Patients aged >18 years with a GERD-Q score of 8.
- Diagnosed with erosive esophagitis by endoscopy. (Los Angeles Classification A-D)
- Patients are willing to undergo a series of therapeutic management.
Exclusion criteria
- Patients with a history of allergy to PCAB or PPI groups.
- Patients with gastric and/or duodenal ulcers.
- Patients with Helicobacter pylori infection.
- Patients with a history of significant systemic disease disorders affecting the esophagus and stomach.
- Patients with a history of malignant disease related to the esophagus and/or stomach.
- Patients with a history of esophageal and/or gastric surgery.
- Pregnant patients
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Indonesia · 5 centers
- Hermina Jatinegara Hospital — East Jakarta
- Cipto Mangunkusumo Hospital — Jakarta Pusat
- Hermina Kemayoran Hospital — Jakarta Pusat
- Hermina Bekasi Hospital — Bekasi
- Hermina Depok Hospital — Depok
Identifiers
NCT: NCT06720610 · INVEST01 · 24-08-1382